Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
20
MCRB Quote, Financials, Valuation and Earnings
Last price:
$15.23
Seasonality move
:
-8.89%
Day range:
$14.65 - $15.09
52-week range:
$6.53 - $29.98
Dividend yield:
0%
P/E ratio:
24.95x
P/S ratio:
376.38x
P/B ratio:
3.04x
Volume:
26.4K
Avg. volume:
187.5K
1-year change:
-10.17%
Market cap:
$132.6M
Revenue:
--
EPS (TTM):
$0.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
-- | -$1.60 | -100% | -11.49% | $21.00 |
|
ALT
Altimmune, Inc.
|
$560 | -$0.24 | -88.8% | -25.34% | $17.75 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
$15.15 | $21.00 | $132.6M | 24.95x | $0.00 | 0% | 376.38x |
|
ALT
Altimmune, Inc.
|
$3.51 | $17.75 | $366.2M | -- | $0.00 | 0% | 13,939.27x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.87 | $0.85 | $739.7M | 9.86x | $0.80 | 0% | 11.41x |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.1K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.26 | $7.00 | $8.7M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
66.11% | 2.425 | 50.61% | 2.16x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.672 | 4.41% | 16.79x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
-$693K | -$22.5M | 4.41% | 16.36% | -6403.7% | $2.2M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Seres Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns MCRB or ALT?
Altimmune, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of -380280%. Seres Therapeutics, Inc.'s return on equity of 16.36% beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About MCRB or ALT?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 38.61%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 405.7%. Given that Altimmune, Inc. has higher upside potential than Seres Therapeutics, Inc., analysts believe Altimmune, Inc. is more attractive than Seres Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 ALTAltimmune, Inc.5 1 1 -
Is MCRB or ALT More Risky?
Seres Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.911% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.037, suggesting its less volatile than the S&P 500 by 96.298%.
-
Which is a Better Dividend Stock MCRB or ALT?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or ALT?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are larger than Altimmune, Inc. quarterly revenues of $5K. Seres Therapeutics, Inc.'s net income of $8.2M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 24.95x while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 376.38x versus 13,939.27x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.376.38x 24.95x $351K $8.2M ALTAltimmune, Inc.13,939.27x -- $5K -$19M
-
Which has Higher Returns MCRB or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of -255.85%. Seres Therapeutics, Inc.'s return on equity of 16.36% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About MCRB or NBY?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 38.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -85.52%. Given that Seres Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Seres Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is MCRB or NBY More Risky?
Seres Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.911% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock MCRB or NBY?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or NBY?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Seres Therapeutics, Inc.'s net income of $8.2M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 24.95x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 376.38x versus 11.41x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.376.38x 24.95x $351K $8.2M NBYNovaBay Pharmaceuticals, Inc.11.41x 9.86x $521K -$1.3M
-
Which has Higher Returns MCRB or OGEN?
Oragenics, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of --. Seres Therapeutics, Inc.'s return on equity of 16.36% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About MCRB or OGEN?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 38.61%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.52%. Given that Oragenics, Inc. has higher upside potential than Seres Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Seres Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 OGENOragenics, Inc.1 0 0 -
Is MCRB or OGEN More Risky?
Seres Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.911% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock MCRB or OGEN?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or OGEN?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are larger than Oragenics, Inc. quarterly revenues of --. Seres Therapeutics, Inc.'s net income of $8.2M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 24.95x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 376.38x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.376.38x 24.95x $351K $8.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns MCRB or PTN?
Palatin Technologies has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of --. Seres Therapeutics, Inc.'s return on equity of 16.36% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M PTNPalatin Technologies-- -- -- -
What do Analysts Say About MCRB or PTN?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 38.61%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Seres Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Seres Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 PTNPalatin Technologies0 0 0 -
Is MCRB or PTN More Risky?
Seres Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.911% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock MCRB or PTN?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or PTN?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are larger than Palatin Technologies quarterly revenues of --. Seres Therapeutics, Inc.'s net income of $8.2M is higher than Palatin Technologies's net income of --. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 24.95x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 376.38x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.376.38x 24.95x $351K $8.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns MCRB or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of --. Seres Therapeutics, Inc.'s return on equity of 16.36% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About MCRB or TOVX?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 38.61%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2613.18%. Given that Theriva Biologics, Inc. has higher upside potential than Seres Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Seres Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is MCRB or TOVX More Risky?
Seres Therapeutics, Inc. has a beta of 0.221, which suggesting that the stock is 77.911% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock MCRB or TOVX?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or TOVX?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Seres Therapeutics, Inc.'s net income of $8.2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 24.95x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 376.38x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.376.38x 24.95x $351K $8.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
BIDU alert for Jan 5
Baidu, Inc. [BIDU] is down 0.42% over the past day.
Buy
69
KORU alert for Jan 5
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 23.79% over the past day.
Buy
62
BE alert for Jan 5
Bloom Energy Corp. [BE] is up 19.51% over the past day.
